Inactive Instrument

News Silence Therapeutics plc London S.E.

Equities

GB0008433350

End-of-day quote London S.E. Other stock markets
- ^GBX	-

Apr. 16	European Equities Traded in the US as American Depositary Receipts Lower in Tuesday Trading	MT
Apr. 15	European Equities Traded in the US as American Depositary Receipts Start Week Higher in Monday Trading	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

European Equities Traded in the US as American Depositary Receipts Lower in Tuesday Trading	Apr. 16	MT
European Equities Traded in the US as American Depositary Receipts Start Week Higher in Monday Trading	Apr. 15	MT
Silence Therapeutics : THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION - Form 6-K	Apr. 15	PU
European Equities Traded in the US as American Depositary Receipts Lower in Friday Trading	Apr. 12	MT
Silence Therapeutics Announces JAMA Publication of Additional Phase 1 Data for Zerlasiran in Subjects with Elevated Lipoprotein(a)	Apr. 08	BU
Silence Therapeutics plc Announces JAMA Publication of Additional Phase 1 Data for Zerlasiran in Subjects with Elevated Lipoprotein(a)	Apr. 08	CI
European Equities Traded in the US as American Depositary Receipts Rise Slightly in Wednesday Trading	Mar. 27	MT
European Equities Traded in the US as American Depositary Receipts Start Week Slightly Lower in Monday Trading	Mar. 18	MT
European Equities Traded in the US as American Depositary Receipts Nudge Lower in Friday Trading	Mar. 15	MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Thursday Trading	Mar. 14	MT
Chardan Boosts Price Target on Silence Therapeutics to $42 From $26 on Positive Data From Zerlasiran Study, Keeps Buy Rating	Mar. 14	MT
Morgan Stanley Boosts Price Target on Silence Therapeutics to $45 From $29, Says Q4 Showed 'Meaningful Progress,' Keeps Overweight Rating	Mar. 14	MT
European Equities Traded in the US as American Depositary Receipts Nudge Lower in Wednesday Trading	Mar. 13	MT
Silence Therapeutics Says Phase 2 Study of High Lipoprotein(a) Treatment Meets Primary Endpoint	Mar. 13	MT
Sector Update: Health Care Stocks Gain Premarket Wednesday	Mar. 13	MT
Transcript : Silence Therapeutics plc, Q4 2023 Earnings Call, Mar 13, 2024	Mar. 13
Silence Therapeutics' 2023 Loss Narrows, Revenue Rises	Mar. 13	MT
Silence Therapeutics Reports Full Year 2023 Financial Results and Recent Business Highlights	Mar. 13	BU
Silence Therapeutics plc Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 13	CI
Silence Therapeutics Announces Positive Topline 36-Week Data from Ongoing Phase 2 Study of Zerlasiran in Patients with High Lipoprotein(a)	Mar. 13	BU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Silence Therapeutics plc London S.E.

Equities

GB0008433350

Summary

Filters